Evidence map›Paper›PMID 25438154›Full record

ArticlePloS one2014

Altered active zones, vesicle pools, nerve terminal conductivity, and morphology during experimental MuSK myasthenia gravis.

Vishwendra Patel, Anne Oh, Antanina Voit, Lester G Sultatos, Gopal J Babu, Brenda A Wilson, Mengfei Ho, Joseph J McArdle

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  4. Review
  5. Muscle-Specific Kinase Myasthenia Gravis.Frontiers in immunology · 2020
    Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Vishwendra PatelDepartment of Pharmacology and Physiology, New Jersey Medical School-Rutgers University, Newark, New Jersey, United States of America.
Anne OhDepartment of Pharmacology and Physiology, New Jersey Medical School-Rutgers University, Newark, New Jersey, United States of America.
Antanina VoitDepartment Cell Biology and Molecular Medicine, New Jersey Medical School-Rutgers University, Newark, New Jersey, United States of America.
Lester G SultatosDepartment of Pharmacology and Physiology, New Jersey Medical School-Rutgers University, Newark, New Jersey, United States of America.
Gopal J BabuDepartment Cell Biology and Molecular Medicine, New Jersey Medical School-Rutgers University, Newark, New Jersey, United States of America.
Brenda A WilsonDepartment of Microbiology, University of Illinois, Urbana-Champaign, Illinois, United States of America.
Mengfei HoDepartment of Microbiology, University of Illinois, Urbana-Champaign, Illinois, United States of America.
Joseph J McArdleDepartment of Pharmacology and Physiology, New Jersey Medical School-Rutgers University, Newark, New Jersey, United States of America.
Rutgers, The State University of New Jersey · USUniversity of Illinois Urbana-Champaign · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies demonstrate reduced motor-nerve function during autoimmune muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG). To further understand the basis of motor-nerve dysfunction during MuSK-MG, we immunized female C57/B6 mice with purified rat MuSK ectodomain. Nerve-muscle preparations were dissected and neuromuscular junctions (NMJs) studied electrophysiologically, morphologically, and biochemically. While all mice produced antibodies to MuSK, only 40% developed respiratory muscle weakness. In vitro study of respiratory nerve-muscle preparations isolated from these affected mice revealed that 78% of NMJs produced endplate currents (EPCs) with significantly reduced quantal content, although potentiation and depression at 50 Hz remained qualitatively normal. EPC and mEPC amplitude variability indicated significantly reduced number of vesicle-release sites (active zones) and reduced probability of vesicle release. The readily releasable vesicle pool size and the frequency of large amplitude mEPCs also declined. The remaining NMJs had intermittent (4%) or complete (18%) failure of neurotransmitter release in response to 50 Hz nerve stimulation, presumably due to blocked action potential entry into the nerve terminal, which may arise from nerve terminal swelling and thinning. Since MuSK-MG-affected muscles do not express the AChR γ subunit, the observed prolongation of EPC decay time was not due to inactivity-induced expression of embryonic acetylcholine receptor, but rather to reduced catalytic activity of acetylcholinesterase. Muscle protein levels of MuSK did not change. These findings provide novel insight into the pathophysiology of autoimmune MuSK-MG.

Indexed as

Neural ConductionAnimalsFemaleImmunization, PassiveMiceMotor EndplateMotor NeuronsMyasthenia Gravis, Autoimmune, ExperimentalNeurotransmitter AgentsProtein Structure, TertiaryRatsReceptor Protein-Tyrosine KinasesReceptors, CholinergicSynaptic VesiclesVaccinationMuSK protein, mouseNeurotransmitter AgentsReceptor Protein-Tyrosine KinasesReceptors, Cholinergic

Identifiers

PMID25438154
PMCPMC4249869
OpenAlexW2070092134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.